follow up of the phase 3 response trial of ruxolitinib in polycythemia vera
Published 9 years ago • 105 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
1:32
response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
-
1:46
results for the follow-up of the response study
-
3:34
a response to ruxolitinib: update on 4-year trial follow-up
-
4:43
the role of ruxolitinib in treating polycythemia vera
-
1:09
significance of findings in response trial in polycythemia vera
-
2:03
results of the phase 3 persist-1 trial of pacritinib in myelofibrosis
-
4:38
tryptamine therapeutics completes phase 1b of iv-infused psilocin trial
-
3:49
utilization of ruxolitinib for polycythemia vera
-
1:13
updated findings after 5-year follow-up for ruxolitinib in pv
-
3:07
further analysis of response trial data validates ruxolitinib as second-line therapy
-
5:19
pivotal ruxolitinib data shows promise for patients with pv
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
1:40
understanding the role of ruxolitinib in patients with polycythemia vera
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
1:33
the safety and efficacy of ruxolitinib in polycythemia vera
-
4:17
pv: treatment with ruxolitinib
-
4:42
response-2 trial: ruxolitinib for pv